Garheng Kong, MD, PhD
Intersouth Partners
Garheng focuses primarily on Intersouth’s life science portfolio. His role at Intersouth involves all aspects of venture investing. He has full-cycle investing experience, successfully sourcing, syndicating, managing, and exiting investments. Prior to joining Intersouth, Garheng worked as a clinical scientist at Glaxo Wellcome, McKinsey & Co. as an associate, and with the Duke University Office of Science and Technology to help commercialize early stage technology. He has performed research in the fields of drug delivery, cancer therapy, bioremediation and self-assembled monolayers. Garheng serves on the board of directors of SEBIO, the North Carolina Biotechnology Center, the Hamner Institutes for Life Sciences and has served on the Duke University Medical Center Institutional Review Board, among others.
He graduated at the top of his class from Duke’s School of Medicine and received his Ph.D. in Biomedical Engineering from Duke University. He received his M.B.A. from Duke’s Fuqua School of Business, where he also graduated at the top of his class. Dr. Kong holds a B.S. in Chemical Engineering and a B.S. in Biological Sciences from Stanford University.